Advertisement

Investigational New Drugs

, Volume 31, Issue 1, pp 136–144 | Cite as

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

  • Glen J. WeissEmail author
  • Ross C. Donehower
  • Tara Iyengar
  • Ramesh K. Ramanathan
  • Karen Lewandowski
  • Eric Westin
  • Karla Hurt
  • Scott M. Hynes
  • Stephen P. Anthony
  • Scott McKane
PHASE I STUDIES

Summary

Purpose This phase I study aims at assessing the safety and tolerability of LY2603618, a selective inhibitor of Checkpoint Kinase 1, in combination with pemetrexed and determining the maximum tolerable dose and the pharmacokinetic parameters. Experimental design This was an open-label, multicenter, dose-escalation study in patients with advanced solid tumors. Increasing doses of LY2603618 (40–195 mg/m2) were combined with 500 mg/m2 of pemetrexed. LY2603618 was administered on Days 1 and 9 and pemetrexed on Day 8 in a 28-day cycle. For all subsequent 21-day cycles, pemetrexed was administered on Day 1 and LY2603618 on Day 2. Antitumor activity was evaluated as per Response Evaluation Criteria in Solid Tumors 1.0. Results A total of 31 patients were enrolled into six cohorts (three at 40 mg/m2 over 4.5-hour infusion, 1-hour infusion in subsequent cohorts: three each at 40 mg/m2, 70 mg/m2, and 195 mg/m2; 13 at 105 mg/m2; six at 150 mg/m2). Four patients experienced a dose-limiting toxicity: diarrhea (105 mg/m2); reversible infusion-related reaction (150 mg/m2); thrombocytopenia (195 mg/m2); and fatigue (195 mg/m2). The maximum tolerated dose was defined as 150 mg/m2. The pharmacokinetic data demonstrated that the exposure of LY2603618 increased in a dose-dependent manner, displayed a suitable half-life for maintaining required human exposures while minimizing the intra- and inter-cycle accumulation, and was unaffected by the pemetrexed administration. The pharmacokinetic-defined biologically efficacious dose was achieved at doses ≥105 mg/m2. Conclusion LY2603618 administered approximately 24 h after pemetrexed showed acceptable safety and pharmacokinetic profiles.

Keywords

LY2603618 Pemetrexed Checkpoint kinase inhibitor Cancer 

Notes

Acknowledgements

This phase I study was funded by Eli Lilly and Company (Study Code: I2I-MC-JMMB). We thank the patients who participated in this trial and the study coordinators, nurse practitioners, clinical research assistants, and doctors who provided valuable assistance in this study. We also thank Dr. Richard Gaynor for his interest and support, Rodney Decker for pharmacokinetic analyst support, and Kate Trenor for project management support and services with Novella Clinical (formerly Prologue Research International), Columbus, OH. We would like to acknowledge the medical writing assistance provided by PRIMO Scientific Corporation, Panama, Rep. of Panama.

Conflicts of interest

GJ Weiss is a consultant/advisory board member of Merrimack Pharmaceuticals, Cephalon, Inc., Eli Lilly and Genzyme Corporation.

References

  1. 1.
    Miller KD, Picus J, Blanke C et al (2000) Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101–103PubMedCrossRefGoogle Scholar
  2. 2.
    Sanchez Y, Wong C, Thoma RS et al (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497–1501PubMedCrossRefGoogle Scholar
  3. 3.
    Karnitz LM, Flatten KS, Wagner JM et al (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636–1644PubMedGoogle Scholar
  4. 4.
    Liu Q, Guntuku S, Cui XS et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448–1459PubMedCrossRefGoogle Scholar
  5. 5.
    Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS (2005) Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65:6835–6842PubMedCrossRefGoogle Scholar
  6. 6.
    Zhao H, Watkins JL, Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 99:14795–14800PubMedCrossRefGoogle Scholar
  7. 7.
    Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376–383PubMedCrossRefGoogle Scholar
  8. 8.
    Tonkinson JL, Marder P, Andis SL et al (1997) Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39:521–531PubMedCrossRefGoogle Scholar
  9. 9.
    Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59:3671–3676PubMedGoogle Scholar
  10. 10.
    Merry C, Fu J, Wang J, Yeh I-Ju, Zhang Y (2010) Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 9:279–283PubMedCrossRefGoogle Scholar
  11. 11.
    Tse AN, Carvajal R, Schwartz GK (2007) Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13:1955–1960PubMedCrossRefGoogle Scholar
  12. 12.
    Marshall M, Barda D, Barnard D et al (2009) Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase I clinical trials. Mol Cancer Ther 8(12 suppl 1):B248CrossRefGoogle Scholar
  13. 13.
    Van Triest B, Pinedo HM, Giaccone G, Peters GJ (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11:385–391PubMedCrossRefGoogle Scholar
  14. 14.
    Giovannetti E, Honeywell R, Hanauske AR et al (2010) Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 11:12–28PubMedCrossRefGoogle Scholar
  15. 15.
    Marshall M, Barnard D, Diaz B et al. (2010) Evaluation of the antitumor activity of pemetrexed in combination with the Chk1 inhibitor LY2603618. Poster presented at 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, Abstract No. 201Google Scholar
  16. 16.
    Hanauske AR, Lahn M, Musib LC et al (2009) Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 20:1565–1575PubMedCrossRefGoogle Scholar
  17. 17.
    Rollins KD, Lindley C (2005) Pemetrexed: a multitargeted antifolate. Clin Ther 27:1343–1382PubMedCrossRefGoogle Scholar
  18. 18.
    Boles NC, Peddibhotla S, Chen AJ, Goodell MA, Rosen JM (2010) Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS One 5:e8581PubMedCrossRefGoogle Scholar
  19. 19.
    Kummar S, Gutierrez ME, Gardner ER et al (2010) A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphoma. Cancer Chemother Pharmacol 65:383–389PubMedCrossRefGoogle Scholar
  20. 20.
    Cullen MH, Zatloukal P, Sörenson S et al (2008) A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19:939–945PubMedCrossRefGoogle Scholar
  21. 21.
    Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10:363–368PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Glen J. Weiss
    • 1
    Email author
  • Ross C. Donehower
    • 2
  • Tara Iyengar
    • 1
  • Ramesh K. Ramanathan
    • 1
  • Karen Lewandowski
    • 1
  • Eric Westin
    • 3
  • Karla Hurt
    • 3
  • Scott M. Hynes
    • 3
  • Stephen P. Anthony
    • 1
  • Scott McKane
    • 4
  1. 1.Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare/TGenScottsdaleUSA
  2. 2.Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA
  3. 3.Eli Lilly and CompanyIndianapolisIndiana
  4. 4.PharmaNet/i3Eden PrairieUSA

Personalised recommendations